Literature DB >> 12131083

Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery.

Anastasios J Karayiannakis1, Konstantinos N Syrigos, Alexandros Polychronidis, Andrew Zbar, Gregory Kouraklis, Constantinos Simopoulos, Gabriel Karatzas.   

Abstract

OBJECTIVE: To evaluate the clinical usefulness of serum vascular endothelial growth factor (VEGF) levels in gastric cancer patients. SUMMARY BACKGROUND DATA: Vascular endothelial growth factor plays an important role in the formation of new blood vessels involved in the growth and metastatic spread of solid tumors, but there is limited information regarding the clinical significance of serum VEGF levels in cancer patients.
METHODS: Serum VEGF concentrations were measured by an enzyme linked immunosorbent assay in 61 healthy controls and in 58 gastric cancer patients before surgery, and then again at 7 and 30 days after surgery. The association between preoperative serum VEGF levels, clinicopathological features and patient survival, and their changes following surgery were evaluated.
RESULTS: Serum VEGF levels in gastric cancer patients were significantly higher than those in controls. There was a significant association between serum VEGF levels and disease stage, as well as invasion depth of the tumor and the presence of distant metastases. Serum VEGF levels decreased significantly after radical resection of the primary tumor and increased in patients with unresectable tumors. Multivariate regression analysis showed that serum VEGF level is an independent prognostic factor for survival.
CONCLUSIONS: Serum VEGF levels in gastric patients are significantly higher compared with normal controls and correlate with local tumor extent, disease stage, and the presence of distant metastases. Preoperative serum VEGF concentration decreases significantly after radical resection of the primary tumor and is an independent prognostic factor for patient survival suggesting that determination of serum VEGF levels may be clinically useful.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12131083      PMCID: PMC1422546          DOI: 10.1097/00000658-200207000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  43 in total

1.  Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma.

Authors:  K Maeda; S M Kang; N Onoda; M Ogawa; Y Kato; T Sawada; K H Chung
Journal:  Cancer       Date:  1999-08-15       Impact factor: 6.860

2.  Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma.

Authors:  A Balsari; J A Maier; M I Colnaghi; S Ménard
Journal:  Lab Invest       Date:  1999-07       Impact factor: 5.662

3.  Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma.

Authors:  H Saito; S Tujitani; M Ikeguchi; M Maeta; N Kaibara
Journal:  Oncology       Date:  1999       Impact factor: 2.935

4.  Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma.

Authors:  H Saito; S Tsujitani; A Kondo; M Ikeguchi; M Maeta; N Kaibara
Journal:  Surgery       Date:  1999-02       Impact factor: 3.982

5.  Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.

Authors:  N Boku; K Chin; K Hosokawa; A Ohtsu; H Tajiri; S Yoshida; T Yamao; H Kondo; K Shirao; Y Shimada; D Saito; T Hasebe; K Mukai; S Seki; H Saito; P G Johnston
Journal:  Clin Cancer Res       Date:  1998-06       Impact factor: 12.531

6.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Authors:  A Kraft; K Weindel; A Ochs; C Marth; J Zmija; P Schumacher; C Unger; D Marmé; G Gastl
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

7.  Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.

Authors:  Y Yamamoto; M Toi; S Kondo; T Matsumoto; H Suzuki; M Kitamura; K Tsuruta; T Taniguchi; A Okamoto; T Mori; M Yoshida; T Ikeda; T Tominaga
Journal:  Clin Cancer Res       Date:  1996-05       Impact factor: 12.531

8.  Serum vascular endothelial growth factor is often elevated in disseminated cancer.

Authors:  P Salven; H Mänpää; A Orpana; K Alitalo; H Joensuu
Journal:  Clin Cancer Res       Date:  1997-05       Impact factor: 12.531

9.  Blood platelets and serum VEGF in cancer patients.

Authors:  P B Vermeulen; P Salven; I Benoy; G Gasparini; L Y Dirix
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

10.  Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer.

Authors:  M Landriscina; A Cassano; C Ratto; R Longo; M Ippoliti; B Palazzotti; F Crucitti; C Barone
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more
  62 in total

1.  Expression of vascular endothelial growth factor in Ewing's sarcoma.

Authors:  Ramakant Kumar; Sukesh Sankineani; Shishir Rastogi; Shyam Prakash; Sameer Bakhshi; Mehar C Sharma; Shahalam Khan; Gopal Sagar D C; Laxman Rijal
Journal:  Int Orthop       Date:  2012-05-29       Impact factor: 3.075

Review 2.  Multi-modality therapy for cancer of the esophagus and GE junction.

Authors:  Mohamedtaki A Tejani; Barbara A Burtness
Journal:  Curr Treat Options Oncol       Date:  2012-09

3.  Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer.

Authors:  Ignasio Gil-Bazo; Ignacio Gil Bazo; Victoria Catalán Goni; Victoria Catalán González; Alvaro Alonso Gutiérrez; Javier Rodríguez Rodríguez; José Antonio Páramo Fernández; Juan de la Cámara Gómez; José Luis Hernández Lizoain; Jesús García-Foncillas López
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

Review 4.  Locally advanced and metastatic gastric cancer: current management and new treatment developments.

Authors:  Kathryn Field; Michael Michael; Trevor Leong
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction.

Authors:  Sylvie Lorenzen; Ben Panzram; Gisela Keller; Florian Lordick; Ken Herrmann; Karin Becker; Ruppert Langer; Markus Schwaiger; Jorg Rudiger Siewert; Katja Ott
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

6.  Prognostic and predictive value of serum vascular endothelial growth factor (VEGF) in squamous cell carcinoma of the head and neck.

Authors:  Bijan Khademi; Mehdi Soleimanpour; Abbas Ghaderi; Mohammad Mohammadianpanah
Journal:  Oral Maxillofac Surg       Date:  2013-03-03

7.  Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection.

Authors:  A Belizon; E Balik; P Horst; D Feingold; T Arnell; T Azarani; V Cekic; R Skitt; S Kumara; R L Whelan
Journal:  Surg Endosc       Date:  2008-01-18       Impact factor: 4.584

Review 8.  Vascular endothelial growth factor a inhibition in gastric cancer.

Authors:  Do Joong Park; Nicholas J Thomas; Changhwan Yoon; Sam S Yoon
Journal:  Gastric Cancer       Date:  2014-07-04       Impact factor: 7.370

9.  Significance of vascular endothelial growth factor expression and its correlation with inducible nitric oxide synthase in gastric cancer.

Authors:  Zhen-Ya Song; Shu-Qun Wen; Jia-Ping Peng; Xuan Huang; Ke-Da Qian
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

10.  Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers.

Authors:  Jia Li; Muhammad Wasif Saif
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.